CARGO Therapeutics (CRGX) announced that its first abstract on CRG-023 will be presented as a poster at the upcoming 66th American Society of ...

该研究开发了一种策略，利用从头设计的结合蛋白（de novo-designed binder，DNDB）代替典型的scFv作为肿瘤表面抗原结合域，以增强CAR-T细胞的抗肿瘤潜力。